hep c dispute, page-9

BTA Holders,
Regarding the nucleoside program for Hepatitis C which involves the Biocryst patent dispute PC indicated that until the dispute/uncertainty was resolved that Big Pahrma would not be interested - particularly as one of the big players Pfizer?? had just written off $2.5bn in a nuclesoide licence that had failed in trials.

In contrast, the Biota non-nucleoside program remains available for licencing out. Apparently the Hepatitis C treatment concept is based on a cocktail of 3 different approaches - nucleoside, non-nucleoside and a third (Reiner will know the details) so Big Pharma needs to put the cocktail together but could be from 3 differnet sources.
Regards
Kangaroo1